Loading quotes...

Forecast

The analysts' average price target is €12.62 (+109.63%). The median is €11.72 (+94.68%).

Buy	19
Hold	6
Sell	1

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

Arvinas focuses on PROTAC pipeline and prepares four clinical programs for data

At the Cantor Fitzgerald conference, Arvinas said the strategic shift from commercialization to advancing its own PROTAC pipeline is largely complete. The company’s cash runway extends into the second half of 2028, enough capital to advance four clinical programs to key Phase I data. Near-term catalysts are data for ARV-393 (lymphomas), LRRK2-102 (neurodegeneration), ARV-027 (Kennedy disease) and ARV-6723 (immuno-oncology); KRAS‑G12D is partner-led only and the PSP program has been pushed regulatory-wise to 2027. The commercial therapy VEPPANNU is being marketed by Rigel; milestone payments and tiered royalties are expected to provide additional revenue. » More on de.investing.com
Arvinas highlights pipeline and upcoming study data at Wells Fargo conference

Arvinas emphasized that with the commercial launch of Vepdegestrant the company is involved with a marketed product for the first time and that liquidity is sufficient through the second half of 2028. Management expects data from four clinical programs within 15 months, including ARV-393 (BCL6) and ARV-102 (LRRK2), is pursuing selective partnerships and will keep key programs such as SBMA in-house. The company sees continued development of its platform but warns of the usual regulatory, safety and execution risks that will determine near-term success. » More on de.investing.com
Arvinas: Q1 revenue plunges, EPS beats expectations and stock rises in premarket

Arvinas reported Q1 2026 revenue of $15.6 million (estimate $17.16 million, Q1 2025: $188.8 million), mainly due to the restructuring of the partnership with Pfizer. Earnings per share were -$0.90, beating the expected -$0.93. The company significantly cut R&D and general & administrative expenses, extended its cash runway into the second half of 2028, and points to FDA approval for VEPPANU as a key milestone. The stock rose 1.45% in premarket trading to $9.80. » More on de.investing.com
Arvinas closes license deal with Rigel and Pfizer for VEPPANU rights

Arvinas and Pfizer received from Rigel the exclusive global rights to develop, manufacture and commercialize VEPPANU (vepdegestrant) for ER-positive, HER2-negative, ESR1-mutant advanced breast cancer. The agreement provides for an upfront payment of $70 million plus $15 million upon completion of certain transition activities, in addition to up to $320 million in milestones and tiered royalties in the mid-teens to mid-twenties percent range. Rigel will handle launch and commercialization in the U.S. and retains global rights with options to grant sublicenses outside the U.S. Arvinas reported Q1 EPS of -$0.90 and said its cash runway extends into the second half of 2028; closing of the transaction is subject to regulatory approvals. » More on de.investing.com
FDA approves Arvinas breast cancer drug VEPPANU – stock jumps sharply

The FDA has approved VEPPANU (vepdegestrant) for the treatment of ER-positive, HER2-negative, ESR1-mutated advanced/metastatic breast cancer after at least one line of endocrine therapy. The approval is considered the first for a PROTAC protein degrader and was granted ahead of the PDUFA date of June 5, 2026. After trading resumed, the Arvinas share rose intraday by up to 13%. » More on de.investing.com

Financials

In the last quarter, ARVINAS INC. DL-,001 had revenue of €441.43k and net profit of -€47.59m

(EUR)	September 2026	YoY
Revenue	441.43k	98.76%
Gross profit	353.14k	99.01%
Net profit	-47.59m	59.10%
EBITDA	-52.18m	82.78%

Fundamentals

Metric	Value
Market capitalization	€407.38m
Number of shares	65.49m
52-week high/low	€13.08 - €5.71
Dividends	No
Beta	1.80
P/E ratio	-46.00
PEG ratio	1.00
P/B ratio	0.88
P/S ratio	1.64

Company profile

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.